(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
German unemployment rate falls to 6.4%, but 3 million still jobless - 2Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- 3Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- 4Poland open to German troops to help secure Ukraine ceasefire
- 5Manual for Tracking down the Mysterious Cascades in China
- Telecommute Arrangement: What's Pivotal for Your Efficiency?
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- No more attempts to free whale stranded off Germany, officials say
- The most effective method to Involve Handshakes for Compromise and Compromise
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Ten Awesome Authentic Realities That Will Leave You Interested
